BB 3

Drug Profile

BB 3

Alternative Names: BB-3; Refanalin

Latest Information Update: 03 Mar 2016

Price : $50

At a glance

  • Originator Angion Biomedica
  • Class Small molecules
  • Mechanism of Action Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Renal failure
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal failure
  • No development reported Heart failure
  • Discontinued Hepatic fibrosis; Myocardial infarction; Stroke

Most Recent Events

  • 01 Jan 2016 Phase-III clinical trials in Renal failure in USA (IV) (NCT02474667)
  • 18 Aug 2015 BB 3 is still in phase II development for Renal failure/delayed graft function in USA
  • 09 Jun 2015 The US FDA approves IND application for BB 3 in Acute kidney injury
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top